N—乙酰半胱氨酸预防老年急性心肌梗死患者PCI术后造影剂肾病的临床研究.docVIP

  • 3
  • 0
  • 约7.21千字
  • 约 9页
  • 2016-12-23 发布于北京
  • 举报

N—乙酰半胱氨酸预防老年急性心肌梗死患者PCI术后造影剂肾病的临床研究.doc

N—乙酰半胱氨酸预防老年急性心肌梗死患者PCI术后造影剂肾病的临床研究   广西壮族自治区北海市人民医院心内科,广西北海 536000   [摘要] 目的 探讨N-乙酰半胱氨酸在预防老年(年龄≥60岁)急性心肌梗死(AMI)患者急诊经皮冠状动脉内介入治疗术(PCI)后造影剂肾病(CIN)中的作用。 方法 以2010年2月~2012年5月在北海市人民医院住院行急诊PCI的109例老年AMI患者为研究对象,随机分为水化+N-乙酰半胱氨酸治疗组(观察组,n = 55)和水化+安慰剂治疗组(对照组,n = 54)。两组均同时予水化治疗,观察组在入院后即刻口服N-乙酰半胱氨酸泡腾片1200 mg,术后3 d,口服N-乙酰半胱氨酸泡腾片1200 mg,2次/d;对照组则于相应的时间给予安慰剂治疗。术后24、48、72 h测定两组患者血清尿素氮(BUN)、血清肌酐(Scr)、肾小球滤过率(GFR)水平。 结果 观察组出现CIN 5例;而对照组发生CIN 14例,两组CIN发生率差异有统计学意义(P 0.05);观察组术后72 h BUN、Scr[(8.23±2.37)mmol/L、(110.50±17.21)μmol/L]低于对照组[(9.47±3.90)mmol/L、(122.66±19.91)μmol/L],GFR高于对照组[(69.09±19.03)mL/min比(60.12±24.57)mL/min],差异有统计学意义(P 0.05)。 结论 N-乙酰半胱氨酸应用于老年急诊PCI患者可减少CIN的发生,有效保护患者肾功能,值得进一步研究。   [关键词] 经皮冠状动脉介入治疗;N-乙酰半胱氨酸;造影剂肾病   [中图分类号] R542.22;R692.3 [文献标识码] A [文章编号] 1673-7210(2014)03(c)-0116-04   Clinical study of N-acetylcysteine in prevention of contrast-induced nephropathy after PCI in elderly patients with acute myocardial infarction   ZHU Hai   Department of Cardiology, Peoples Hospital of Beihai City, Guangxi Zhuang Autonomous Region, Beihai 536000, China   [Abstract] Objective To investigate the effect of N-acetylcysteine in prevention of contrast-induced nephropathy (CIN) after primary percutaneous intervention (emergency PCI) in elderly patients (aged≥60 years) with acute myocardial infarction (AMI). Methods 109 elderly patients with AMI who underwent emergency PCI from February 2010 to May 2012 in Peoples Hospital of Beihai City were selected as research objects. All patients were randomly divided into Hydration + N-acetylcysteine treatment group (observation group, n = 55) and Hydration + placebo treatment group (control group, n = 54). Two groups were all given hydration therapy at the same time, the observation group was immediately given N-acetylcysteine effervescent 1200 mg (oral) after admission, In 3 days after PCI, patients were given N-acetylcysteine Effervescent Tablets 1200 mg (oral), 2 times/d; control group was given placebo treatment at the appropriat

文档评论(0)

1亿VIP精品文档

相关文档